2nd Quarter - Report
CHRISTOPHER MOYER for CAMERON COMPANIES
Firm
Client
Income
$10,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
The President's FY 2020 Budget as it relates to site neutral payment policies and funding for the National Institutes of Health, monitored the introduction of drug pricing legislation for its potential impact on existing and emerging cancer drug therapies. Monitored Medicare reimbursement developments in the agencies and Congress for alternative cancer therapies, such as CAR-T.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER MOYER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.